STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non–Small Cell Lung Cancer With No Actionable Gene Alterations
Delvys Rodríguez‐Abreu, Joaquim Bosch‐Barrera, Jhanelle E. Gray, Myung‐Ju Ahn, Melissa L. Johnson, Xinwei Yu, Saad Mohammad, Xueying Chen, Trever Todd, Jong-Seok Kim, Martin Reck
Topics & Concepts
MedicinePembrolizumabChemotherapyLung cancerOncologyInternal medicineCancer researchCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment